Amgen at 52-Week High on Solid Earnings, Test Results

By CARLOS MARTINEZ
Staff Reporter

With its stock hovering around its 52-week high in recent weeks, Amgen Inc. appears poised for another quarter of solid earnings and high volume of sales of its rheumatoid arthritis drugs....

Subscribe to get the full story.


Are you a subscriber? Sign In